does ranitidine cause cancer
Does ranitidine cause cancer
And its answer is yes. This friday us fda officially announced that ranitidine has a contaminated element named NDMA which means nitrosodimethylamine
Ranitidine is a very common drug which used to treat acidity and peptic ulcer specially. Its most popular brand are in india is tab rantac, tab zantac, tab ranidom rd and tab aciloc.
This this video for more detail if you are using this tablet india. This video is in hindi language which help you to do for further thing about this matter
๐๐๐๐๐๐๐๐๐๐๐๐๐
I hope you watch this video and gets important information regarding this tablet.
Popular antacid tablets containing Ranitidine might be carcinogenic. The Ministry of Health and Prevention (MoHAP) has issued a circular to all health facilities and practitioners, informing them about the precautionary suspension of the registration, importation and distribution of all medicines containing ranitidine, while asking patients to continue with their current medication until replacement is found.
A commonly used acidity-controlling drug ranitidine is giving heartburn to numerous drug manufacturers, regulators and the public worldwide, including in India. This is after a US-based online pharmacy alerted regulators that its sample tests revealed the drug to contain some cancer-causing impurities beyond permissible levels.
Although leading regulators such as the and the European Medicines Agency (EMA) have not banned the drug, regulators have alerted public to be cautious and consult their doctors. However, many leading drugmakers, including India's Dr Reddy's Laboratories, have stopped sales until there is clarity. The Indian drug regulator and the Indian Medical Association are yet to come up with a warning to public and manufacturers. Swiss drug maker Novartis's generic arm Sandoz has also recalled the drug voluntarily.
An old molecule with most versions off-patent, the global ranitidine market that includes tablets, syrups and injections usually prescribed for intestinal and stomach ulcers, Gastroesophageal Reflux Disease (GERD), esophagitis, Zollinger-Ellison syndrome and others was valued at $412.4 million in 2017. The drug and its variants are expected to grow at a compound annual growth rate (CAGR) of 1.8 per cent to reach $485.4 million by 2026, says a market forecast by Coherent Market Insights.
In India, various drugmakers such as Dr Reddy's, Sun Pharma, Cadila Pharma, GlaxoSmithKline, JB Chemicals and Zydus Cadila sell over 180 products based on ranitidine. The domestic market sales are pegged at around Rs 700-750 crore. Aurobindo Pharma, Granules India, and Strides Shasun are some of companies that got approval to sell this product in the US. "Most generic drugmakers target $5-10 million sales from such old molecules as these steadily contribute to their annual sales," said sources.
The FDA said it has been investigating the carcinogen, called N-nitrosodimethylamine or NDMA, in blood pressure and heart failure medicines since last year and is evaluating whether low levels pose a risk to patients.
“The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options,” the FDA said in the statement.
I hope this article is usefull for use. Please like this article if it is usefull and follow us and share this article that help him to aware about this matter
Thanks
And its answer is yes. This friday us fda officially announced that ranitidine has a contaminated element named NDMA which means nitrosodimethylamine
Ranitidine is a very common drug which used to treat acidity and peptic ulcer specially. Its most popular brand are in india is tab rantac, tab zantac, tab ranidom rd and tab aciloc.
This this video for more detail if you are using this tablet india. This video is in hindi language which help you to do for further thing about this matter
๐๐๐๐๐๐๐๐๐๐๐๐๐
I hope you watch this video and gets important information regarding this tablet.
Popular antacid tablets containing Ranitidine might be carcinogenic. The Ministry of Health and Prevention (MoHAP) has issued a circular to all health facilities and practitioners, informing them about the precautionary suspension of the registration, importation and distribution of all medicines containing ranitidine, while asking patients to continue with their current medication until replacement is found.
A commonly used acidity-controlling drug ranitidine is giving heartburn to numerous drug manufacturers, regulators and the public worldwide, including in India. This is after a US-based online pharmacy alerted regulators that its sample tests revealed the drug to contain some cancer-causing impurities beyond permissible levels.
Although leading regulators such as the and the European Medicines Agency (EMA) have not banned the drug, regulators have alerted public to be cautious and consult their doctors. However, many leading drugmakers, including India's Dr Reddy's Laboratories, have stopped sales until there is clarity. The Indian drug regulator and the Indian Medical Association are yet to come up with a warning to public and manufacturers. Swiss drug maker Novartis's generic arm Sandoz has also recalled the drug voluntarily.
An old molecule with most versions off-patent, the global ranitidine market that includes tablets, syrups and injections usually prescribed for intestinal and stomach ulcers, Gastroesophageal Reflux Disease (GERD), esophagitis, Zollinger-Ellison syndrome and others was valued at $412.4 million in 2017. The drug and its variants are expected to grow at a compound annual growth rate (CAGR) of 1.8 per cent to reach $485.4 million by 2026, says a market forecast by Coherent Market Insights.
In India, various drugmakers such as Dr Reddy's, Sun Pharma, Cadila Pharma, GlaxoSmithKline, JB Chemicals and Zydus Cadila sell over 180 products based on ranitidine. The domestic market sales are pegged at around Rs 700-750 crore. Aurobindo Pharma, Granules India, and Strides Shasun are some of companies that got approval to sell this product in the US. "Most generic drugmakers target $5-10 million sales from such old molecules as these steadily contribute to their annual sales," said sources.
The FDA said it has been investigating the carcinogen, called N-nitrosodimethylamine or NDMA, in blood pressure and heart failure medicines since last year and is evaluating whether low levels pose a risk to patients.
“The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options,” the FDA said in the statement.
I hope this article is usefull for use. Please like this article if it is usefull and follow us and share this article that help him to aware about this matter
Thanks
Comments
Post a Comment